contact us
After NICE rejected Novartis’ migraine prevention drug Aimovig in draft guidance issued in January, it was inundated with comments that forced a delay to its final appraisal document. That’s now out – and the answer is still no.
Do Not Allow Advertisers to Use My Personal information
